Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154864 | 0.84 | ALDH1A1 (0.41) | CYP3A4TP53ALDH1A1MAPT | |
| SCHEMBL3786242 | 0.84 | TSHR (0.35) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL13019811 | 0.84 | TSHR (0.42) | CYP3A4TP53MAPT | |
| SCHEMBL30105030 | 0.79 | CYP3A4 (0.48) | CYP3A4TP53ALDH1A1MAPT | |
| SCHEMBL4427069 | 0.79 | CYP3A4 (0.48) | CYP3A4TP53ALDH1A1MAPT | |
| SCHEMBL15934242 | 0.77 | GABRA1 (0.34) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL29371018 | 0.76 | CYP3A4 (0.55) | CYP3A4TP53ALDH1A1 | |
| SCHEMBL291988 | 0.76 | CYP3A4 (0.55) | CYP3A4TP53ALDH1A1 | |
| SCHEMBL16585078 | 0.75 | DDR1 (0.31) | — | |
| SCHEMBL16957559 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP3A4 177/4885TP53 2819/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.